This coronary stent enables physicians to access and unblock difficult-to-treat blockages
Abbott, announced the launch of XIENCE Sierra Everolimus (drug) Eluting Coronary Stent System in India. XIENCE Sierra is one of the latest generation stents in the XIENCE family and is now available to patients with blocked coronary arteries. For interventional cardiologists, it provides safety for the complex cases.
Abbott’s development of tools and devices has improved the angioplasty procedure over the years. Percutaneous coronary intervention (PCI), also called coronary angioplasty, is a nonsurgical, minimally invasive procedure that improves blood flow to the heart. Physicians use PCI to open blood vessels to the heart that are narrowed or blocked by plaque. Often, a small mesh tube called a stent is placed to keep the artery open.
A statement from the company informs, “XIENCE Sierra improves upon its previous versions with an enhanced stent design, a new delivery system, and unique sizes to treat challenging cases. With a specialised coating to reduce re-blockage XIENCE stents collectively have a safety record from more than 120+ clinical trials involving 120,000 patients. As per published data, the stent has proved efficacy in difficult to treat, narrowed lesions and patients with complex conditions.”
It adds, “XIENCE Sierra’s features include greater expansion range. This is helpful when the heart vessel is of different sizes at both ends. Importantly, the stent offers stability due to its high longitudinal strength that minimises the risk of its deformation. It can be better pushed and tracked so that physicians have more confidence in outcomes and safety for their patients. It allows physicians to perform tough techniques with more ease such as maneuvering and crossing through complex calcified lesions. One of the unique offerings with XIENCE Sierra is that it’s easy to use which helps treat challenging anatomies in patients with complex conditions.”